DFP-14927 for Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called DFP-14927 for individuals with solid tumors that haven't responded to other treatments. The goal is to determine a safe dose and assess how the body processes the drug. It targets those whose cancer has returned or hasn't improved with standard treatments. Individuals diagnosed with solid tumors such as gastroesophageal, pancreatic, or bile duct cancer, and who are not responding to current treatments, might be suitable candidates. Participants will receive the treatment through weekly IV infusions in 28-day cycles. As a Phase 1 trial, participants will be among the first to receive this new treatment, aiding researchers in understanding its effects in people.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, you cannot have had chemotherapy, immunotherapy, radiotherapy, or other investigational therapies within 4 weeks before starting the study.
Is there any evidence suggesting that DFP-14927 is likely to be safe for humans?
Research has shown that DFP-14927 is very safe for patients with advanced solid tumors. Participants tolerated the treatment well, experiencing no severe side effects. The medicine was administered through an intravenous infusion, delivering it directly into the bloodstream once a week. Patients generally managed this method well. Although all treatments can have side effects, early research suggests DFP-14927 is safe for humans.12345
Why do researchers think this study treatment might be promising?
Researchers are excited about DFP-14927 because it introduces a fresh approach to cancer treatment. Unlike traditional chemotherapy drugs that attack both healthy and cancerous cells, DFP-14927 is designed to selectively target cancer cells, potentially reducing side effects. Additionally, it is administered via a weekly IV infusion on a 28-day cycle, which may offer more consistent and controlled dosing compared to some existing treatments. This targeted mechanism and delivery method could provide a more effective and patient-friendly option in the fight against cancer.
What evidence suggests that DFP-14927 might be an effective treatment for cancer?
Research shows that DFP-14927, the investigational treatment in this trial, may help treat certain types of cancer. Lab studies have demonstrated that this treatment stops cancer cells from multiplying by halting them at a specific stage. It also showed effects against tumors in animal studies, particularly for pancreatic cancer. In earlier trials, patients with advanced solid tumors experienced extended periods without disease progression, suggesting the treatment might help control tumor growth. Overall, these findings suggest that DFP-14927 could be effective in fighting hard-to-treat cancers.12678
Who Is on the Research Team?
Jaffer Ajani, MD
Principal Investigator
M.D. Anderson Cancer Center
Are You a Good Fit for This Trial?
This trial is for adults over 18 with advanced solid tumors that haven't responded to standard treatments or lack effective treatment options. Specifically, it includes those with certain types of gastroesophageal, pancreatic, or cholangiocarcinoma cancers. Participants must be relatively healthy overall (ECOG status 0-1) and have adequate organ function.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive weekly IV infusion of DFP-14927 in a 28-day cycle to determine safety, efficacy, and maximum tolerated dose
Pharmacokinetics Assessment
Pharmacokinetics and bioavailability of DFP-14927 are assessed during the first cycle
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- DFP-14927
Find a Clinic Near You
Who Is Running the Clinical Trial?
Delta-Fly Pharma, Inc.
Lead Sponsor